These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34126389)

  • 1. Simultaneous characterization of insulin HMWP and protamine sulphate in complex formulations through SEC-coupled mass spectrometry.
    Srivatsa K; Gokhale Y; Chakrabarti PP; Kulshrestha A; Vajpai N
    J Pharm Biomed Anal; 2021 Sep; 203():114188. PubMed ID: 34126389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin.
    Hjorth CF; Hubálek F; Andersson J; Poulsen C; Otzen D; Naver H
    Pharm Res; 2015 Jun; 32(6):2072-85. PubMed ID: 25583030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel protein cross-linking reaction in stressed Neutral Protamine Hagedorn formulations of insulin.
    Beavis RC; Kneirman MD; Sharknas D; Heady MA; Frank BH; DeFelippis MR
    J Pharm Sci; 1999 Mar; 88(3):331-6. PubMed ID: 10052992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of site-specific heterogeneity in peptide drugs using intact mass spectrometry with electron transfer dissociation.
    Gucinski AC; Boyne MT
    Rapid Commun Mass Spectrom; 2014 Aug; 28(15):1757-63. PubMed ID: 24975256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of insulin NPH formulations.
    Norrman M; Hubálek F; Schluckebier G
    Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
    J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of protamine peptides in insulin drug products using reversed phase high performance liquid chromatography.
    Hvass A; Skelbaek-Pedersen B
    J Pharm Biomed Anal; 2005 Mar; 37(3):551-7. PubMed ID: 15740916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.
    Chang LC; Lee HF; Yang Z; Yang VC
    AAPS PharmSci; 2001; 3(3):E17. PubMed ID: 11741268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.
    Blanco C; Castillo R; Quiralte J; Delgado J; García I; de Pablos P; Carrillo T
    Allergy; 1996 Jun; 51(6):421-4. PubMed ID: 8837667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products.
    Ehkirch A; Hernandez-Alba O; Colas O; Beck A; Guillarme D; Cianférani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():176-183. PubMed ID: 29684909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic distribution of proteins in solution by mass spectrometry: The analysis of insulin analogues.
    Fávero-Retto MP; Guerreiro LH; Pessanha CM; Palmieri LC; Lima LMTR
    Biologicals; 2017 Jan; 45():69-77. PubMed ID: 28341309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.
    Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ
    J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, Aggregation, and Activity of a Covalent Insulin Dimer Formed During Storage of Neutral Formulation of Human Insulin.
    Hjorth CF; Norrman M; Wahlund PO; Benie AJ; Petersen BO; Jessen CM; Pedersen TÅ; Vestergaard K; Steensgaard DB; Pedersen JS; Naver H; Hubálek F; Poulsen C; Otzen D
    J Pharm Sci; 2016 Apr; 105(4):1376-86. PubMed ID: 26921119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography.
    Hoffmann JA; Chance RE; Johnson MG
    Protein Expr Purif; 1990 Nov; 1(2):127-33. PubMed ID: 2136234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of protamine peptides in insulin pharmaceutical formulations by capillary electrophoresis.
    Lamalle C; Servais AC; Demelenne A; Crommen J; Fillet M
    J Sep Sci; 2016 Mar; 39(6):1189-94. PubMed ID: 26829340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
    Duchateau J; Schreyen H; Dorchy H
    Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of electrospray ionization mass spectrometry as a tool for characterization of small soluble protein aggregates.
    Wang G; Johnson AJ; Kaltashov IA
    Anal Chem; 2012 Feb; 84(3):1718-24. PubMed ID: 22240037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity.
    Barstad RM; Stephens RW; Hamers MJ; Sakariassen KS
    Thromb Haemost; 2000 Feb; 83(2):334-7. PubMed ID: 10739395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of branched ultrahigh molar mass polymers by asymmetrical flow field-flow fractionation and size exclusion chromatography.
    Otte T; Pasch H; Macko T; Brüll R; Stadler FJ; Kaschta J; Becker F; Buback M
    J Chromatogr A; 2011 Jul; 1218(27):4257-67. PubMed ID: 21238968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.